Clinical trials: Secondary Cancer
Gastro-enteropancreatic Neuroendocrine Tumor, Secondary Malignant Neoplasm of Liver
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Imaging with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging) is normally used to see how tumors respond to treatment. If tumors shrink after therapy, doctors continue with the same treatment.
- Trial name
- NCT01423734
- Testing
- magnetic resonance imaging (MRI)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Malignant Neoplasm of Breast
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Palbociclib, the first oral CDK4/6 inhibitor, is an approved medicine indicated for the treatment of a kind of advanced/metastatic breast cancer (MBC), called hormone receptors positive (HR+)/ Human epidermal growth factor…
- Trial name
- NCT06495164
- Testing
- Palbociclib, Aromatase inhibitor, Ribociclib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Breast Neoplasms
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone…
- Trial name
- NCT02258464
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Background hormonal therapy
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 99 people
- Sponsor
- Bayer
Insomnia, Secondary, Sleep Disturbance
Robustness and Usability of the Dreem 3 System for at Home Sleep Monitoring in an Insomnia Population.
There is an unmet medical need for monitoring sleep for multiple nights in a patient's home, without the inconvenience of traveling and staying overnight in a medical center, and without the need for a technician to set up a…
- Conditions
- Insomnia, Secondary, Sleep Disturbance, Sleep, Sleep Initiation and Maintenance Disorders
- Trial name
- NCT05611099
- Testing
- Dreem 3 System vs WatchPAT One, Usability Questionnaire
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Dreem
Oligo-metastatic Prostate Carcinoma
Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer
The existing large prospective study demonstrates the benefits of primary radiotherapy in patients with low-volume oligo-metastatic prostate cancer (OMPC), and there is also more evidence of the benefits of local…
- Trial name
- NCT06198387
- Testing
- hormone and RT, ADT combined with abiraterone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Changhai Hospital
Metastatic Gastrointestinal Cancer, Genitourinary Cancer
Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)
Analysis of cell free DNA(cfDNA), unlike tissue biopsy, presents a new tool for the monitoring and treatment of cancer. The investigators have developed a differentiated sequencing assay, Digital Sequencing Technology (DST) that…
- Trial name
- NCT02140463
- Where
- South Korea
- Volunteers
- 229 people
- Sponsor
- Samsung Medical Center
Kidney Cancer
Bortezomib in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276614
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Esophageal Varices in Cirrhosis of the Liver
HVPG-Guided Therapy Versus EVL Plus NSBB in Second Prophylaxis of Esophageal Variceal Bleeding
A single-center randomized controlled study comparing endoscopic or interventional therapy guided by the hepatic venous pressure gradient (HVPG) , to standard endosopic variceal ligation plus nonselective beta-blocker therapy…
- Trial name
- NCT03687216
- Testing
- HVPG-guided therapy, Routing Therapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- West China Hospital
Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
This is a Phase II clinical trial evaluating the efficacy and safety of a new treatment approach for patients with locally advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes on the opposite side of the…
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
- Trial name
- SACTION 2501 (NCT07309952)
- Testing
- Sintilimab, Paclitaxel, Carboplatin (AUC 5)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Yang Hong
NSCLC
SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases
Vertebral metastases are events that affect the quality of life of tumor patients, and are often accompanied by severe pain at the site of metastasis and even by the risk of compression fracture.
- Trial name
- NCT05577052
- Testing
- Metastatic vertebrae treated with SBRT
- Volunteers
- 100 people
- Sponsor
- Wuhan University
Diabetic Macular Edema
Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study
Intravitreal injections of pegaptanib every 4 weeks will be efficacious in treating Diabetic Macular Edema (DME), as compared to injections every 6 weeks.
- Trial name
- PRESERVE (NCT01486238)
- Testing
- Macugen® pegaptanib sodium
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Valley Retina Institute
Digestive Cancer
A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan
This study is to determine the Maximal Tolerated Dose (MTD), the Dose Limitant Toxicities (DLTs) and the safety profile of S-1 combined with fixed doses of Irinotecan (SIRI schedule) and fixed doses of Irinotecan and Oxaliplatin…
- Trial name
- SIRINOX (NCT02387138)
- Testing
- S-1, Irinotecan, Oxaliplatin
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Metastatic Breast Cancer
Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)
Nab-paclitaxel has demonstrated to be an active agent in breast cancer and probably a less toxic alternative to solvent based taxanes. It is indicated in metastatic breast cancer after failure of anthracyclines.
- Trial name
- NCT01416558
- Testing
- Nab-Paclitaxel
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- GBG Forschungs GmbH
HCC - Hepatocellular Carcinoma
QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
This is a phase I trial to assess the safety and preliminary efficacy of QL1706 in Treating Advanced Hepatocellular Carcinoma Patients refractory to prior immunotherapy.
- Trial name
- QL1706 (NCT06822985)
- Testing
- QL1706
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Wan-Guang Zhang
Neuroendocrine Tumor, Liver Metastases
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most promising therapeutic options.
- Conditions
- Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour
- Trial name
- LUTARTERIAL (NCT04837885)
- Testing
- Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection
- Where
- 4 sites in France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Bordeaux
Recurrent Colon Cancer, Recurrent Rectal Cancer
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of capecitabine when given together with GTI-2040 and oxaliplatin in treating patients with locally advanced or metastatic colorectal cancer or other solid tumors.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
- Trial name
- NCT00084643
- Testing
- GTI-2040, oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Prostate Cancer
Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer
Evaluation of patient reported outcomes (PRO) / QoL regarding typical ailments in real-life patients with bone metastases treated with osteoprotective agents.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Metastases
- Trial name
- PROBone (NCT02410044)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG
Advanced/Metastatic NSCLC
Impact of Circadian Rhythm on Immunotherapy
This study aims to determine whether morning versus afternoon treatment impacts efficacy of (standard of care) immunotherapy in a broad patient population.
- Trial name
- NCT07224971
- Testing
- Immunotherapy - PD-1 Blocker
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Liza Villaruz, MD
Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors.
- Conditions
- Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00055809
- Testing
- PEG-interferon alfa-2b, bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral Neuropathy, Secondary to Drugs or Chemicals
Peripheral Blood Biomarkers Associated With CIPN
The investigators are doing a research study that will teach us about the tingly pain that people develop when they get chemotherapy.
- Trial name
- NCT02661399
- Volunteers
- 100 people
- Sponsor
- St. Louis University